{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:59:46Z","timestamp":1790258386933,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myotonic dystrophy (DM) is a multisystemic disorder characterized by significant heterogeneity in symptom manifestation, progression, and severity. This variability complicates clinical trial design and implementation, thereby affecting therapeutic development. This study aimed to identify barriers to clinical trial readiness in DM and explore actionable solutions by incorporating perspectives from pharmaceutical partners, clinical trial site staff, people living with DM (PLDM), and caregivers. Focus groups, surveys, and interviews were conducted with pharmaceutical partners (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200965), PLDM and caregivers (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200935), principal investigators (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912), and clinical research coordinators (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). Qualitative findings were thematically analyzed and triangulated with survey data to enhance validity. Three major barriers consistently emerged: (1) a lack of comprehensive, validated endpoints that capture outcomes meaningful to patients; (2) insufficient data sharing and coordination across industry; and (3) challenges in trial design, recruitment, and participant burden. PLDM emphasized under-studied but debilitating symptoms\u2014such as dysphagia, fatigue, and cognitive impairment\u2014that are rarely prioritized in clinical trials. Pharmaceutical partners cited regulatory uncertainty surrounding composite outcome measures as well as the value of quantitative myotonia indicators as informative holistic disease indicators. Limited access to natural history data, often prohibitively costly for smaller companies, reinforces competitive rather than collaborative dynamics. PLDM and caregivers also highlighted substantial financial, logistical, and accessibility challenges associated with trial participation. Participants favored several strategies to address these barriers: (1) convening a multi-stakeholder scientific session with the U.S. Food and Drug Administration (FDA) and establishing a working group to define and standardize patient-centered, clinically relevant endpoints; (2) developing a comprehensive, coordinated registry that integrates existing data sources, longitudinal health and study data, genetic diagnostic data, supports recruitment and refinement of study inclusion criteria, and enables post-market surveillance; (3) strengthening trial site preparedness and anticipating recruitment needs, including biomarker-driven cohorts; and (4) adopting patient-centered trial designs that minimize burden, with patient advocacy groups (PAGs) serving a central convening and advocacy role by bringing various groups together to discuss these topics. While barriers to DM clinical trial readiness are significant, they are addressable. Coordinated action among industry, regulators, clinicians, and advocacy groups\u2014guided by patient priorities\u2014will be essential. Implementing these strategies could accelerate therapeutic development, improve trial inclusivity, and ultimately enhance quality of life for individuals living with DM.\n                  <\/jats:p>","DOI":"10.1186\/s13023-026-04408-0","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:44:25Z","timestamp":1781739865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring barriers to clinical trial readiness among the myotonic dystrophy community: a mixed-methods study"],"prefix":"10.1186","volume":"21","author":[{"given":"Julia Stellmann","family":"Wrenn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ryan-Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hellthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-6430","authenticated-orcid":false,"given":"Andy","family":"Rohrwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"4408_CR1","doi-asserted-by":"crossref","unstructured":"Johnson NE, Butterfield RJ, Maybe K, Newcomb T, Imburgia C, Dunne D, et al. Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program. Neurology. 2021;96(7):1045-53. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33472919\/","DOI":"10.1212\/WNL.0000000000011425"},{"key":"4408_CR2","unstructured":"National Organization for Rare Disorders. Myotonic dystrophy [Internet]. 2017 [cited 2025 Jun 30]. Available from: https:\/\/rarediseases.org\/rare-diseases\/dystrophy-myotonic\/"},{"key":"4408_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780199571970.001.0001","volume-title":"Myotonic dystrophy","author":"PS Harper","year":"2009","unstructured":"Harper PS. Myotonic dystrophy. Oxford: Oxford University Press; 2009."},{"issue":"21","key":"4408_CR4","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1093\/nar\/23.21.4303","volume":"23","author":"GK Smith","year":"1995","unstructured":"Smith GK, Jie J, Fox GE, Gao X. DNA CTG triplet repeats involved in dynamic mutations of neurologically related gene sequences form stable duplexes. Nucleic Acids Res. 1995;23(21):4303\u201311. https:\/\/doi.org\/10.1093\/nar\/23.21.4303. PMID: 7501450; PMCID: PMC307384.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"4408_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","volume":"11","author":"B Udd","year":"2012","unstructured":"Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11(10):891\u2013905.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4408_CR6","first-page":"154","volume":"32","author":"G Meola","year":"2013","unstructured":"Meola G. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol. 2013;32(3):154\u201365. PMID: 24803843; PMCID: PMC4006279.","journal-title":"Acta Myol"},{"key":"4408_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ng0297-190","volume":"15","author":"G Gourdon","year":"1997","unstructured":"Gourdon G, Radvanyi F, Lia AS, Duros C, Blanche M, Abitbol M, et al. Moderate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice. Nat Genet. 1997;15:190\u20132. https:\/\/doi.org\/10.1038\/ng0297-190.","journal-title":"Nat Genet"},{"key":"4408_CR8","doi-asserted-by":"crossref","unstructured":"Ho G, Cardamone M, Farrar M. Congenital and childhood myotonic dystrophy: current aspects of disease and future directions. World J Clin Pediatr. 2015;4(4):66\u201380. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4637811\/","DOI":"10.5409\/wjcp.v4.i4.66"},{"key":"4408_CR9","doi-asserted-by":"publisher","unstructured":"Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta. 2007;1772(2):195\u2013204. https:\/\/doi.org\/10.1016\/j.bbadis.2006.05.013. PMID: 16876389.","DOI":"10.1016\/j.bbadis.2006.05.013"},{"key":"4408_CR10","unstructured":"National Organization for Rare Disorders. Myotonic dystrophy \u2013 symptoms, causes, treatment [Internet]. 2017 [cited 2025 Jul 7]. Available from: https:\/\/rarediseases.org\/rare-diseases\/dystrophy-myotonic\/"},{"key":"4408_CR11","doi-asserted-by":"publisher","unstructured":"Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60(4):657\u2009\u2013\u200964. https:\/\/doi.org\/10.1212\/01.wnl.0000054481.84978.f9. PMID: 12601109.","DOI":"10.1212\/01.wnl.0000054481.84978.f9"},{"issue":"3","key":"4408_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1042\/ETLS20230015","volume":"7","author":"S Rajagopal","year":"2023","unstructured":"Rajagopal S, Donaldson J, Flower M, Hensman Moss DJ, Tabrizi SJ. Genetic modifiers of repeat expansion disorders. Emerg Top Life Sci. 2023;7(3):325\u201337. https:\/\/doi.org\/10.1042\/ETLS20230015. PMID:37861103; PMCID:PMC10754329.","journal-title":"Emerg Top Life Sci"},{"key":"4408_CR13","doi-asserted-by":"crossref","unstructured":"Centofanti F, Visconti VV, D\u2019Apice MR, et al. The novel (TCTG)n motif in CNBP expanded alleles: composition, dynamics and genotype\u2013phenotype correlation in myotonic dystrophy type 2 (DM2). Hum Genomics 2026; in press.","DOI":"10.1186\/s40246-026-00954-7"},{"issue":"12","key":"4408_CR14","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.3390\/ijms241210129","volume":"24","author":"VV Visconti","year":"2023","unstructured":"Visconti VV, Macr\u00ec E, D\u2019Apice MR, Centofanti F, Massa R, Novelli G, Botta A. In cis effect of DMPK expanded alleles in myotonic dystrophy type 1 patients carrying variant repeats at 5\u2032 and 3\u2032 ends of the CTG array. Int J Mol Sci. 2023;24(12):10129. https:\/\/doi.org\/10.3390\/ijms241210129.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4408_CR15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41431-025-01907-9","volume":"33","author":"H Swinkels","year":"2025","unstructured":"Swinkels H, Leferink M, Pennings M, van der Sanden B, Gilissen C, Galbany JC, Kamsteeg EJ. Interrupted CTG repeats in the 37\u201343 units size range in the 3\u2032UTR of DMPK are common alleles. Eur J Hum Genet. 2025;33(11):1547\u201353. https:\/\/doi.org\/10.1038\/s41431\u2011025\u201101907\u20119. PMID:40624398; PMCID:PMC12583562.","journal-title":"Eur J Hum Genet"},{"key":"4408_CR16","doi-asserted-by":"crossref","unstructured":"Hujoel MLA, Handsaker RE, Tang D, Kamitaki N, Mukamel RE, Rubinacci S, Palamara PF, McCarroll SA, Loh PR. Insights into DNA repeat expansions among 900,000 biobank participants. Nature. 2026;650(8103):920\u20139. https:\/\/doi.org\/10.1038\/s41586\u2011025\u201109886\u2011z. PMID:41501457; PMCID:PMC12935551.","DOI":"10.1038\/s41586-025-09886-z"},{"key":"4408_CR17","doi-asserted-by":"crossref","unstructured":"Pounraja VK, Sul JH, Herman J et al. Population\u2013scale repeat expansions elucidate disease risk and brain atrophy. Nature. 2026; advance online publication. https:\/\/doi.org\/10.1038\/s41586\u2013026\u201310345\u20136","DOI":"10.1038\/s41586-026-10345-6"},{"issue":"3","key":"4408_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/16501970500477967","volume":"38","author":"G Antonini","year":"2006","unstructured":"Antonini G, Soscia F, Giubilei F, De Carolis A, Gragnani F, Morino S, et al. Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. J Rehabil Med. 2006;38(3):181\u20135. https:\/\/doi.org\/10.1080\/16501970500477967.","journal-title":"J Rehabil Med"},{"key":"4408_CR19","doi-asserted-by":"publisher","unstructured":"Ferchichi Y, Natividad \u00c0, Artero R, L\u00f3pez-Castel A. The myotonic dystrophy type 1 drug development pipeline: 2026 Edition. Drug Discov Today. 2026 May 27:104706. https:\/\/doi.org\/10.1016\/j.drudis.2026.104706.\u00a0PMID: 42208802.","DOI":"10.1016\/j.drudis.2026.104706"},{"key":"4408_CR20","doi-asserted-by":"publisher","unstructured":"Lumsden JM, Urv TK. The rare diseases clinical research network: a model for clinical trial readiness. Ther Adv Rare Dis. 2023;4. https:\/\/doi.org\/10.1177\/26330040231219272.","DOI":"10.1177\/26330040231219272"},{"key":"4408_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s43441-020-00221-4","volume":"55","author":"R Huml","year":"2020","unstructured":"Huml R, Dawson J, Bailey M, Nakas N, Williams J, Kolochavina M, et al. Accelerating rare disease drug development: lessons learned from muscular dystrophy patient advocacy groups. Ther Innov Regul Sci. 2020;55:370.","journal-title":"Ther Innov Regul Sci"},{"key":"4408_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40900-023-00535-1","volume":"10","author":"P Furlong","year":"2024","unstructured":"Furlong P, Dugar A, White M. Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials. Res Involv Engagem. 2024;10:1. https:\/\/doi.org\/10.1186\/s40900-023-00535-1.","journal-title":"Res Involv Engagem"},{"issue":"1","key":"4408_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/14737167.2020.1734454","volume":"20","author":"NL Crossnohere","year":"2020","unstructured":"Crossnohere NL, Fischer R, Crossley E, Vroom E, Bridges JF. The evolution of patient-focused drug development and Duchenne muscular dystrophy. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):57\u201368. https:\/\/doi.org\/10.1080\/14737167.2020.1734454.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4408_CR24","unstructured":"Myotonic Dystrophy Foundation. 2023 Myotonic dystrophy research landscape assessment [Internet]. 2023 Dec 22 [cited 2025 Oct 1]. Available from: https:\/\/www.myotonic.org\/2023-myotonic-dystrophy-research-landscape-assessment"},{"key":"4408_CR25","unstructured":"University of Utah. More examples of precision medicine in action [Internet]. Learn.Genetics; n.d. [cited 2025 Oct 8]. Available from: https:\/\/learn.genetics.utah.edu\/content\/precision\/action\/"},{"key":"4408_CR26","unstructured":"Balch B. Making medicine personal: moving away from a one-size-fits-all approach to health care [Internet]. AAMC; 2024 Feb 22 [cited 2025 Oct 8]. Available from: https:\/\/www.aamc.org\/news\/making-medicine-personal-moving-away-one-size-fits-all-approach-health-care"},{"issue":"3","key":"4408_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/MOP.0000000000000351","volume":"28","author":"SL Martiniano","year":"2016","unstructured":"Martiniano SL, Sagel SD, Zemanick ET. Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr. 2016;28(3):312\u20137. https:\/\/doi.org\/10.1097\/MOP.0000000000000351.","journal-title":"Curr Opin Pediatr"},{"key":"4408_CR28","doi-asserted-by":"publisher","unstructured":"Gatto F, Benemei S, Piluso G. The complex landscape of DMD mutations: moving towards personalized medicine. Front Genet. 2024;15. https:\/\/doi.org\/10.3389\/fgene.2024.1360224.","DOI":"10.3389\/fgene.2024.1360224"},{"key":"4408_CR29","doi-asserted-by":"publisher","unstructured":"Cerecedo-Zapata CM, Guerra-Grajeda A, M\u00e1rquez-Quir\u00f3z LC, Arciga-Portela P, Escobar-Cedillo RE, Jim\u00e9nez-Guti\u00e9rrez GE, et al. Fifteen Years of Myotonic Dystrophy Type 1 in Mexico: Clinical, Molecular, and Socioeconomic Insights from a National Reference Cohort. Genes (Basel). 2025;16(12):1515. https:\/\/doi.org\/10.3390\/genes16121515.\u00a0PMID: 41465188; PMCID: PMC12732758.","DOI":"10.3390\/genes16121515"},{"key":"4408_CR30","doi-asserted-by":"publisher","unstructured":"van As D, Claeys T, Salz R, et al. Large\u2013scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity. J Neuromuscul Dis. 2026;0(0). https:\/\/doi.org\/10.1177\/22143602251410443.","DOI":"10.1177\/22143602251410443"},{"issue":"11","key":"4408_CR31","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1038\/s41591-024-03190-5","volume":"30","author":"K Iba\u00f1ez","year":"2024","unstructured":"Iba\u00f1ez K, Jadhav B, Zanovello M, Gagliardi D, Clarkson C, Facchini S, et al. Increased frequency of repeat expansion mutations across different populations. Nat Med. 2024;30(11):3357\u201368. https:\/\/doi.org\/10.1038\/s41591\u2013024\u201303190\u20135. PMID:39354197; PMCID:PMC11564083.","journal-title":"Nat Med"},{"key":"4408_CR32","doi-asserted-by":"publisher","unstructured":"Overend G, L\u00e9gar\u00e9 C, Mathieu J, Bouchard L, Gagnon C, Monckton DG. Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. Hum Mol Genet. 2019;28(13):2245\u201354. https:\/\/doi.org\/10.1093\/hmg\/ddz055. PMID: 31220271; PMCID: PMC6586140.","DOI":"10.1093\/hmg\/ddz055"},{"key":"4408_CR33","doi-asserted-by":"publisher","unstructured":"Morales F, V\u00e1squez M, Corrales E, Vindas-Smith R, Santamar\u00eda-Ulloa C, Zhang B, et al. Longitudinal increases in somatic mosaicism of the expanded CTG repeat in myotonic dystrophy type 1 are associated with variation in age-at-onset. Hum Mol Genet. 2020;29(15):2496\u20132507. https:\/\/doi.org\/10.1093\/hmg\/ddaa123. PMID: 32601694.","DOI":"10.1093\/hmg\/ddaa123"},{"key":"4408_CR34","doi-asserted-by":"publisher","unstructured":"Hageman IC, van Rooij IALM, de Blaauw I, Trajanovska M, King SK. A systematic overview ofrare disease patient registries: challenges in design, quality management, and maintenance. Orphanet J Rare Dis. 2023;18(1):106. https:\/\/doi.org\/10.1186\/s13023-023-02719-0. PMID: 37147718; PMCID: PMC10163740.","DOI":"10.1186\/s13023-023-02719-0"},{"key":"4408_CR35","doi-asserted-by":"publisher","unstructured":"Al-Jedai A, Al-Mudaiheem H, AlSakran A, Bashiri FA, Ghamdi F, Almuhaizea MA, et al. Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements. Cost Eff Resour Alloc. 2025;23(1). https:\/\/doi.org\/10.1186\/s12962-025-00647-3.","DOI":"10.1186\/s12962-025-00647-3"},{"issue":"19","key":"4408_CR36","doi-asserted-by":"publisher","first-page":"14873","DOI":"10.3390\/ijms241914873","volume":"24","author":"I Angilletta","year":"2023","unstructured":"Angilletta I, Ferrante R, Giansante R, Lombardi L, Babore A, Dell\u2019Elice A, Alessandrelli E, Notarangelo S, Ranaudo M, Palmarini C, De Laurenzi V, Stuppia L, Rossi C. Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies. Int J Mol Sci. 2023;24(19):14873. https:\/\/doi.org\/10.3390\/ijms241914873. PMID:37834320; PMCID:PMC10573646.","journal-title":"Int J Mol Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04408-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04408-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04408-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:26Z","timestamp":1790255186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04408-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4408"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04408-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8961613\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was determined to be exempt by the Advarra Institutional Review Board (IRB) as Pro00081721. All participants were informed of the potential risks and benefits of their participation through verbal or written informed consent processes (or a combination of the two).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants consented to use of the data collected for this research for publication. Additionally, all data has been de-identified.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"329"}}